Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared to Platinum-Based Chemotherapy in Research Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With EGFR Mutation After Failure of osimertinib
